Drug intelligence / Profile preview

AMG 171

Development stage: Discontinued
Lead developer: Amgen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

AMG 171 is a recombinant fusion protein and analogue of growth differentiation factor 15 (GDF-15), developed by Amgen for the treatment of obesity. It was designed to act as a GDF-15 replacement therapy, modulating the GDF-15 pathway to influence metabolic processes related to weight regulation. The drug reached Phase 1 clinical trials for obesity but development was discontinued before further advancement[1][3][5].

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on AMG 171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 171.

Explore the full profile